Kyverna Therapeutics amends loan facility with Oxford Finance, extends Term A draw period to Dec 31, 2026

Kyverna Therapeutics, Inc.

Amendment extends availability of remaining $15M Term A loans through Dec 31, 2026; upfront fee of $187,500.
If full $15M not drawn by Dec 31, 2026, non-utilization fee of 1% of undrawn amount applies.
If full $15M drawn, Term B loan availability extended to Sep 30, 2027; Term C loans restructured into two $20M tranches with revenue/clinical milestones.
Minimum revenue covenants begin Q2 2027 or later depending on capital raises; original facility up to $150M with $25M drawn in Nov 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.